- Home
- EVAX vs SYRS Comparison
EVAX vs SYRS Comparison
Compare EVAX & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- SYRS
- Stock Information
- Founded
- EVAX 2008
- SYRS 2011
- Country
- EVAX Denmark
- SYRS United States
- Employees
- EVAX N/A
- SYRS N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- SYRS Health Care
- Exchange
- EVAX Nasdaq
- SYRS Nasdaq
- Market Cap
- EVAX 8.7M
- SYRS 7.1M
- IPO Year
- EVAX 2021
- SYRS 2016
- Fundamental
- Price
- EVAX $2.41
- SYRS $0.20
- Analyst Decision
- EVAX Strong Buy
- SYRS Hold
- Analyst Count
- EVAX 2
- SYRS 5
- Target Price
- EVAX $11.00
- SYRS $3.00
- AVG Volume (30 Days)
- EVAX 250.1K
- SYRS 3.2M
- Earning Date
- EVAX 10-31-2024
- SYRS 10-31-2024
- Dividend Yield
- EVAX N/A
- SYRS N/A
- EPS Growth
- EVAX N/A
- SYRS N/A
- EPS
- EVAX N/A
- SYRS N/A
- Revenue
- EVAX $3,295,000.00
- SYRS $386,000.00
- Revenue This Year
- EVAX $4,845.21
- SYRS N/A
- Revenue Next Year
- EVAX $30.30
- SYRS N/A
- P/E Ratio
- EVAX N/A
- SYRS N/A
- Revenue Growth
- EVAX N/A
- SYRS N/A
- 52 Week Low
- EVAX $2.38
- SYRS $0.18
- 52 Week High
- EVAX $68.05
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- EVAX 23.50
- SYRS 35.88
- Support Level
- EVAX $2.38
- SYRS $0.20
- Resistance Level
- EVAX $3.90
- SYRS $0.25
- Average True Range (ATR)
- EVAX 0.51
- SYRS 0.03
- MACD
- EVAX -0.05
- SYRS 0.02
- Stochastic Oscillator
- EVAX 2.72
- SYRS 5.19
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.